Diagnostic accuracy of 99mTc-HYNIC-TOC SPECT/CT for detecting osteomalacia-associated tumors

作者：Bo Li, Lili Duan, Xiali Li, Jingqi Shi, Huiqiang Li, Huimin Liu, Xiaoliang Cheng, Xinyu Wu, Yongju Gao · 发表于：Frontiers in Oncology · 年份：2023 · DOI：10.3389/fonc.2023.1228575 · 被引用次数：4 · 研究领域：Parathyroid Disorders and Treatments、Medical Imaging and Pathology Studies、Bone health and treatments

Objectives Tumor-induced osteomalacia (TIO) is a rare acquired paraneoplastic disorder characterized by hypophosphatemia resulting from tumor-secreted fibroblast growth factor-23 (FGF23). Surgical resection of the culprit TIO is the first choice of treatment. However, TIO is difficult to detect with conventional diagnostic tools due to its small size and variable location in the body. Somatostatin receptor scintigraphy (SSR) has recently emerged as a functional molecular imaging choice for TIO detection and localization. This research was undertaken to evaluate the efficacy of 99m Tc-labeled hydrazinonicotinyl-Tyr3-octreotide ( 99m Tc-HYNIC-TOC) SPECT/CT in detecting TIO. Methods 99m Tc-HYNIC-TOC SPECT/CT and the available clinical data of 25 patients with suspected TIO were analyzed retrospectively. The 99m Tc-HYNIC-TOC SPECT/CT findings were compared with the post-surgical pathology diagnosis and clinical follow-up results. Results Using 99m Tc-HYNIC-TOC SPECT/CT, suspicious tumors were found in 18 of the 25 patients, and 15 of them underwent surgical resection. The post-operative pathology confirmed a TIO in those 13 patients whose symptoms and biochemical anomalies gradually resolved after the surgery. The remaining five patients were finally considered false positives. Moreover, the 99m Tc-HYNIC-TOC SPECT/CT results were negative in seven patients, with six patients being true negative (4 patients were diagnosed with acquired Fanconi syndrome and 2 patients responded wel...